Status:
COMPLETED
Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients.
Lead Sponsor:
Lo.Li.Pharma s.r.l
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
60-99 years
Phase:
NA
Brief Summary
Mellitus type 2 diabetes (T2MD) is a chronic disease characterized by high glucose plasmatic level due to an alteration of insulin function. Several authors have correlated this altered function to an...
Eligibility Criteria
Inclusion
- With diagnosis of Type 2 Mellitus Diabetes for at least 1 year
- Levels of Hb1Ac ranging from 7.5% to 9.0%
Exclusion
- Patients that require insulin treatment
- Treated at baseline with food supplements or drugs containing Myo-inositol, D-chiro-inositol, alphalactalbumin, zinc, or Gymnema Sylvestre;
- Any contraindications to the treatment or to any substance used for the treatment
- Subjects with intestinal malabsorption
- Patients subjected to surgery within 6 months before baseline;
- Chronic treatment with systemic corticosteroids
Key Trial Info
Start Date :
February 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2022
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04745780
Start Date
February 10 2021
End Date
December 22 2022
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Basilio Pintaudi
Milan, Italy, 20162